187 related articles for article (PubMed ID: 23068190)
1. Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center.
Costa WL; Coimbra FJ; Fogaroli RC; Ribeiro HS; Diniz AL; Begnami MD; Mello CA; Fanelli MF; Silva MJ; Fregnani JH; Montagnini AL
Radiat Oncol; 2012 Oct; 7():169. PubMed ID: 23068190
[TBL] [Abstract][Full Text] [Related]
2. Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy.
Jácome AA; Wohnrath DR; Scapulatempo Neto C; Fregnani JH; Quinto AL; Oliveira AT; Vazquez VL; Fava G; Martinez EZ; Santos JS
Gastric Cancer; 2013 Apr; 16(2):233-8. PubMed ID: 22740060
[TBL] [Abstract][Full Text] [Related]
3. [Adjuvant chemo radiotherapy after gastrectomy and D2 lymphadenectomy in patients with gastric cancer in the National Institute of Cancer, Lima, Peru].
Montenegro P; Flores L; Quintana S; Casanova L; Ruíz E; León J; Mantilla R
Rev Gastroenterol Peru; 2013; 33(1):34-8. PubMed ID: 23539054
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of N-ratio in selecting patients for adjuvant chemoradiotherapy after d2-gastrectomy.
Costa Junior WL; Coimbra FJ; Batista TP; Ribeiro HS; Diniz AL
Arq Gastroenterol; 2013; 50(4):257-63. PubMed ID: 24474226
[TBL] [Abstract][Full Text] [Related]
5. Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.
Kim Y; Squires MH; Poultsides GA; Fields RC; Weber SM; Votanopoulos KI; Kooby DA; Worhunsky DJ; Jin LX; Hawkins WG; Acher AW; Cho CS; Saunders N; Levine EA; Schmidt CR; Maithel SK; Pawlik TM
Surgery; 2017 Aug; 162(2):285-294. PubMed ID: 28578142
[TBL] [Abstract][Full Text] [Related]
6. Lymph Node Burden as a Predictive Factor for Selective Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer After a D2 Dissection: A Retrospective Study.
Li Q; Li G; Palmer JD; Zhang Z
Am J Clin Oncol; 2017 Aug; 40(4):375-380. PubMed ID: 25503428
[TBL] [Abstract][Full Text] [Related]
7. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
[TBL] [Abstract][Full Text] [Related]
8. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER?
Andreollo NA; Drizlionoks E; Tercioti-Junior V; Coelho-Neto JS; Ferrer JAP; Carvalheira JBC; Lopes LR
Arq Bras Cir Dig; 2019; 32(4):e1464. PubMed ID: 31859917
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience.
Ghidini M; Donida BM; Totaro L; Ratti M; Pizzo C; Benzoni I; Lomiento D; Aldighieri F; Toppo L; Ranieri V; Senti C; Tanzi G; Martinotti M; Passalacqua R; Rovatti M; Tomasello G
Clin Transl Oncol; 2020 Jul; 22(7):1004-1012. PubMed ID: 31599376
[TBL] [Abstract][Full Text] [Related]
10. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer.
Mrena J; Mattila A; Böhm J; Jantunen I; Kellokumpu I
World J Gastroenterol; 2015 Dec; 21(47):13294-301. PubMed ID: 26715812
[TBL] [Abstract][Full Text] [Related]
11. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
Dikken JL; Jansen EP; Cats A; Bakker B; Hartgrink HH; Kranenbarg EM; Boot H; Putter H; Peeters KC; van de Velde CJ; Verheij M
J Clin Oncol; 2010 May; 28(14):2430-6. PubMed ID: 20368551
[TBL] [Abstract][Full Text] [Related]
12. Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity-score matched analysis.
Diniz TP; da Costa WL; Fonseca de Jesus VH; Ribeiro HSC; Diniz AL; de Godoy AL; de Farias IC; Torres SM; Felismino TC; Coimbra FJF
J Surg Oncol; 2020 Apr; 121(5):823-832. PubMed ID: 31950511
[TBL] [Abstract][Full Text] [Related]
13. The addition of chemoradiation to adjuvant chemotherapy is associated with improved survival in lymph node-positive gastric cancer.
Altman AM; Sheka AC; Marmor S; Lou E; Reynolds M; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Surg Oncol; 2020 Sep; 34():134-139. PubMed ID: 32891318
[TBL] [Abstract][Full Text] [Related]
14. Is there a role for surgery with adequate nodal evaluation alone in gastric adenocarcinoma?
Dudeja V; Habermann EB; Abraham A; Zhong W; Parsons HM; Tseng JF; Al-Refaie WB
J Gastrointest Surg; 2012 Feb; 16(2):238-46; discussion 246-7. PubMed ID: 22089951
[TBL] [Abstract][Full Text] [Related]
15. Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center.
Norero E; Bustos M; Herrera ME; Cerda J; González P; Ceroni M; Martínez C; Briceño E; Rojas H; Cártes R; Lopez V; Hidalgo V; Báez S; Caracci M; Viñuela E; Díaz A
Eur J Surg Oncol; 2016 Jan; 42(1):94-102. PubMed ID: 26577767
[TBL] [Abstract][Full Text] [Related]
16. Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
Park SH; Sohn TS; Lee J; Lim DH; Hong ME; Kim KM; Sohn I; Jung SH; Choi MG; Lee JH; Bae JM; Kim S; Kim ST; Park JO; Park YS; Lim HY; Kang WK
J Clin Oncol; 2015 Oct; 33(28):3130-6. PubMed ID: 25559811
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy.
In H; Kantor O; Sharpe SM; Baker MS; Talamonti MS; Posner MC
Ann Surg Oncol; 2016 Jun; 23(6):1956-62. PubMed ID: 26753752
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study.
Kaytan Saglam E; Yucel S; Balik E; Saglam S; Asoglu O; Yamaner S; Bugra D; Oral EN; Kizir A; Kapran Y; Sakar B; Akyuz A; Gulluoglu M
J Cancer Res Clin Oncol; 2015 Feb; 141(2):361-7. PubMed ID: 25189794
[TBL] [Abstract][Full Text] [Related]
19. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Lee SJ; Sohn TS; Lee J; Park SH; Park JO; Lim DH; Park YS; Lim HY; Choi MG; Lee JH; Bae JM; Kim S; Kang WK
Anticancer Res; 2014 Nov; 34(11):6585-91. PubMed ID: 25368262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
